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Introduction: Malignant glaucoma occurs when the intraocular pressure elevates in the setting of a shallow anterior
chamber and patent iridectomy. We describe a case in which malignant glaucoma that was refractory to conventional
treatment and complete vitrectomy was successfully managed by rerouting the glaucoma tubes into the pars plana.
Case presentation: A 47-year-old Latino man had a history of neovascular glaucoma and subsequent peripheral
anterior synechiae. He was status post-two glaucoma drainage devices. He developed pupillary block. Laser iridotomy
was performed without complications. He subsequently developed malignant glaucoma that was refractory to yttrium
aluminum garnet capsulohyaloidotomy of the anterior hyaloid. He underwent pars plana vitrectomy with successful
control of his intraocular pressure. After 2 weeks, the malignant glaucoma recurred. He underwent repositioning of the
tubes into the pars plana with successful control of his intraocular pressure.
Conclusion: In rare cases of malignant glaucoma refractive to yttrium aluminum garnet hyaloidotomy and vitrectomy,
placement of glaucoma drainage devices is a reasonable alternative.
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Malignant glaucoma was first introduced in 1869 by Dr
von Graefe. It is a condition consisting of elevated intra-
ocular pressure (IOP) with shallow anterior chamber
despite a patent iridectomy. Risk factors include hyper-
opia, narrow angle, and a history of miotic use. It can
occur following any intraocular surgery [1] (cataract or
glaucoma) or laser procedures [2,3] and has also been
reported in eyes that have not undergone any procedures.
It is typically treated medically with cycloplegia, aqueous
suppression, and osmotic agents, or with neodymium-
doped yttrium aluminum garnet (YAG) laser capsulo-
hyaloidotomy or surgical disruption of the anterior hyaloid
[4]. In cases that are refractory to the above, pars plana
vitrectomy with or without lensectomy has been used
[3,5-10].
We report a case in which a patient who was refractory
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reproduction in any medium, provided the orinto the pars plana cavity. There is one other case re-
port of a single tube insertion into the pars plana with vi-
trectomy [11]. This is the first reported case of rerouting
two tubes from the anterior chamber into the pars
plana for the treatment of malignant glaucoma after the
patient’s malignant glaucoma recurred following pars
plana vitrectomy.Case presentation
A 47-year-old Latino man with poorly controlled dia-
betes developed neovascular glaucoma in both eyes
(OU) with maximal IOPs in the 40mmHg range OU. His
past ocular history was significant for proliferative dia-
betic retinopathy, s/p panretinal photocoagulation lasers
OU and multiple AvastinW (bevacizumab) injections by
the retina specialist. The patient was on maximal medi-
cations. He had undergone glaucoma drainage devices
OU with BaerveldtW 101–350 (Abbott Medical Optics,
Inc.) to his right eye (OD) and left eye (OS) 5 months
later. His IOP OD elevated again despite an addition of
five glaucoma medications and oral acetazolamide, so atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Slit lamp photo of patient following placement of
glaucoma tubes into the pars plana.
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inferotemporal quadrant.
One year later, his IOPs were 8mmHg OD and 16mmHg
OS. His visual acuity OD was 20/200. He was taking max-
imal medications OU again. His visual acuity OD wors-
ened to count fingers vision OD. He underwent cataract
extraction OD, which improved his visual acuity to 20/
125. His IOPs were maintained in the mid-teens range;
he refused further glaucoma surgery until his visual fields
worsened to 3° OD and 6° OS. Oral acetazolamide 500mg
twice a day was added. He continued to refuse surgical
intervention despite worsening visual fields.
Six months later, he developed iris bombe OD. He
underwent laser iridotomy, which lowered his IOP to
12mmHg. Two weeks later, his IOP OD increased to
80mmHg. He had a flat anterior chamber, with iris
enveloping both the superotemporal and inferotemporal
glaucoma tubes. Neither cycloplegia nor YAG capsulo-
hyaloidotomy OD helped to lower his IOP or deepen his
anterior chamber. He underwent emergent pars plana
vitrectomy OD with removal of the anterior hyaloid that
evening. His anterior chamber deepened significantly,
and his IOPs lowered to 12mmHg. He was placed on
topical steroids every 2 hours and was stable for 2 weeks
with a patent iridotomy. His IOP rose again to 80mmHg
with a flat anterior chamber despite a patent iridotomy.
He underwent rerouting of both glaucoma tubes into
the pars plana cavity that evening. The next day, his IOP
was 11mmHg with a deep anterior chamber (Figure 1).
His IOP has remained stable since then with the addition
of glaucoma medications and cycloplegic agents; however,
his visual acuity had decreased to hand motions.
Discussion
Pars plana vitrectomy has been found to be efficacious
in the treatment of malignant glaucoma following cataractextraction [9,10]. Pars plana vitrectomies have either been
combined with cataract extraction and posterior capsu-
lectomy [12] or combined with trabeculectomy [13] in
select patients who have significant peripheral anterior
synechiae. Cekic and Batman [14] recommended that con-
comitant lensectomy be performed in order to save the
patient a second surgical procedure in the future. Tube
placement into the pars plana at the same time as pars
plana vitrectomy has been reported previously [11].
This is the second case of a tube implant in the pars
plana and the first reported incidence of repositioning
glaucoma tubes into the pars plana cavity to treat malig-
nant glaucoma. There has been a reported case [15] of a
patient's eye having recurrent malignant glaucoma des-
pite having undergone vitrectomy in which the anterior
hyaloid was left intact. Our patient’s iridotomy was pa-
tent despite significant posterior synechiae. It is possible
that he developed an inflammatory membrane over the
iridotomy; however, the iridotomy was patent. Our pa-
tient had had a complete vitrectomy and removal of the
anterior hyaloid. In addition the original iridotomy was
enlarged using the vitreous cutter probe via pars plana.
However, rerouting of the tubes into the posterior cavity,
in close proximity to where aqueous production occurs,
helped break the cycle of malignant glaucoma.Conclusions
This report demonstrates that patients who are refractory
to conventional treatment for malignant glaucoma can
benefit from rerouting of the glaucoma tube(s) into the
pars plana; this can be done at the same time as the vitrec-
tomy if the risk for further visual deterioration is high.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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